HRH3
Histamine H3 receptor
As of the edition of 20 October 2026, HRH3 (histamine H3 receptor, UniProt Q9Y5N1) has 17 drugs tested at it and 12 companies on the list, 9 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9Y5N1
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 8
- Disease areas
- Mental health; Nervous system; Ear, nose and throat; Lungs and airways; Nutrition and metabolism; Immune system; Chemically induced; Inherited and neonatal
- Registered trials of its drugs
- 96
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 10 |
| Stopped | 4 |
| Status not established | 1 |
| Total | 17 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Pitolisant | Marketed | Phase 4 | Ends 2033 |
| Betahistine | Marketed | Phase 4 | none listed |
| Bavisant | Went quiet | Phase 2 | none listed |
| AZD5213 | Went quiet | Phase 2 | none listed |
| GSK239512 | Went quiet | Phase 2 | none listed |
| MK-0249 | Stopped | Phase 2 | none listed |
| ABT-288 | Went quiet | Phase 2 | none listed |
| PF-03654746 | Stopped | Phase 2 | none listed |
| PF-03654764 | Stopped | Phase 2 | none listed |
| GSK189254 | Stopped | Phase 2 | none listed |
| MK3134 | Went quiet | Phase 1 | none listed |
| SUVN-G3031 | Status not established | Phase 2 | none listed |
12 of 17 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 9 |
| Engaged | 1 |
| Undetermined | 2 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| Merck & Co. | Route A |
| Pfizer | Route A |
| AstraZeneca | Route A |
The other 9 companies at HRH3
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at HRH3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.